Michelle R. Mahoney

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

Sandra P. D’Angelo, Michelle R. Mahoney, Brian Andrew Van Tine et al. · The Lancet Oncology · 2018 · 748 citations · Full text

Medicine, Oncology, Pharmacology +11

Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study

Steven R. Alberts, William L. Horvath, William C. Sternfeld et al. · Journal of Clinical Oncology · 2005 · 541 citations · Full text

Medicine, Oncology, Surgery +17

Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer

Philip A. Philip, Michelle R. Mahoney, Cristine Allmer et al. · Journal of Clinical Oncology · 2005 · 459 citations · Full text

Medicine, Oncology, Pharmacology +15

Sorafenib for Advanced and Refractory Desmoid Tumors

Mrinal M. Gounder, Michelle R. Mahoney, Brian A. Van Tine et al. · New England Journal of Medicine · 2018 · 449 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).

Alan P. Venook, Donna Niedzwiecki, Heinz‐Josef Lenz et al. · Journal of Clinical Oncology · 2014 · 406 citations

Medicine, Oncology, Pharmacotherapy +14